Search

Your search keyword '"Kevin A. David"' showing total 106 results

Search Constraints

Start Over You searched for: Author "Kevin A. David" Remove constraint Author: "Kevin A. David" Search Limiters Full Text Remove constraint Search Limiters: Full Text
Sorry, I don't understand your search. ×
106 results on '"Kevin A. David"'

Search Results

1. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

2. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Catalog

Books, media, physical & digital resources

3. Oncogenic Integration of Nucleotide Metabolism via Fatty Acid Synthase in Non-Hodgkin Lymphoma

4. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

5. Baryons, salt and popcorn in holographic QCD

6. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 <scp>U.S.</scp> cancer centers

8. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

9. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL

10. Burkitt Lymphoma International Prognostic Index

11. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

13. SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence

14. The Burkitt Lymphoma International Prognostic Index (BL-IPI)

15. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

16. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

17. Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis

18. Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

19. EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

20. Management of older Hodgkin lymphoma patients

21. Interaction Kinetics with Transcriptomic and Secretory Responses of CD19 CAR Natural Killer Cell Therapy in CD20 Resistant Non-Hodgkin Lymphoma

22. Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure

23. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

24. How I treat advanced Hodgkin lymphoma - a global view

25. Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma: Phase 1 Results of a Multicenter Phase 1/2 Clinical Trial

26. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

27. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

28. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy

29. A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

30. Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

31. Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

32. Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)

33. Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

34. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

35. Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

36. The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx

37. The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

38. Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma

39. Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

40. Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

41. Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

42. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience

43. Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

44. A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

45. Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis

46. SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)

47. Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy

48. A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

49. Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy

50. Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy